Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 7/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14053968 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL1850656 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL27272428 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL17031906 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL1336739 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL3050914 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL8337646 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL4847115 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL14865498 | 0.99 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ACEPREP | |
| Cesium SCHEMBL8725844 | 0.99 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ACEPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349945-B | HCV inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-108349907-B | 1,4(1,4) -diphenylheterocycle hexa-tomato-12,43-diyl derivatives, process for their preparation and their use | 江苏豪森药业集团有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-105801467-A | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heterapahanes and meatllocenes useful for treating HCV infections | 艾其林医药公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-103561739-B | Substituted aliphatics, cyclophenes, isophenes, heteroarenes, hetero-isophenes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-03-02 | — | — | CN | disclosed |
| CN-103561739-A | Substituted aliphatics, cyclophenes, isophenes, heteroarenes, hetero-isophenes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS INC | 2014-02-05 | — | — | CN | disclosed |
| US-7439036-B2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1536017-B1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1615885-A1 | B -FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1536017-A2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-19 | — | — | US | disclosed |
| WO-2004092132-A1 | [B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | IDO1, IDO2, APEH | CHRM2 478/4885CHRM1 235/4885CHRM3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.